PharmaCorp Rx Inc.
PCRX.V
TSX
| 09/30/2025 | 06/30/2025 | ||||
|---|---|---|---|---|---|
| Revenue | 9.74% | 13.79% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | 9.74% | 13.79% | |||
| Cost of Revenue | 7.89% | 15.24% | |||
| Gross Profit | 12.55% | 11.67% | |||
| SG&A Expenses | 18.78% | 62.28% | |||
| Depreciation & Amortization | 18.42% | 4.36% | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 12.67% | 29.74% | |||
| Operating Income | -51.55% | -250.31% | |||
| Income Before Tax | -88.82% | -165.24% | |||
| Income Tax Expenses | -112.00% | 52.06% | |||
| Earnings from Continuing Operations | -6.56% | -257.34% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -1,208.33% | 113.95% | |||
| Net Income | -11.82% | -264.65% | |||
| EBIT | -51.55% | -250.31% | |||
| EBITDA | -84.36% | -143.39% | |||
| EPS Basic | -8.33% | -271.43% | |||
| Normalized Basic EPS | -100.00% | -169.23% | |||
| EPS Diluted | -8.33% | -271.43% | |||
| Normalized Diluted EPS | -100.00% | -169.23% | |||
| Average Basic Shares Outstanding | 0.00% | 0.00% | |||
| Average Diluted Shares Outstanding | 0.00% | 0.00% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||